semaglutide asa guidelines Relationship between residual gastric content and peri‐operative semaglutide use assessed by gastric ultrasound: a prospective observational study - Nersessian - 2024 AHA/ASA Guidelines 2026

Description

Orders placed before 3:30 PM ET are processed same day

All patients should be assessed for hemodynamic compromise, the severity of illness with or without scoring systems, and end-organ damage to determine the need for intensive care resources

"Classifications for Intrauterine Devices | CDC"

Phase III results for retatrutide are set to be released later in 2025 and in early 2026, but an earlier phase II trial recorded between a 7.2% and 17.5% reduction in body weight after 24 weeks, depending on the dose (7.2% on 1mg, 17.5% on 12mg), and up to a 24.2% reduction in body weight after 48 weeks for those on 12mg (-8.7% change for those on 1mg) 8